CCM
RPRX

Camber Capital Management’s Repros Therapeutics Inc. RPRX Stock Holding History

Camber Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-390,370
Closed -$6.75M – 50
2014
Q2 		$6.75M Buy
+390,370
New +$6.36M 0.44% 37

Other funds holding RPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DCM
Destrier Capital Management New York $144M AUM 7.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

Camber Capital Management's RPRX Position: Q3 2014 in Review

Camber Capital Management sold out of Repros Therapeutics Inc. (RPRX) in Q3 2014, closing a stake of 390,370 shares — an estimated $6.75M sold.

Camber Capital Management first reported a position in RPRX in Q2 2014 and held it in 1 quarter. The position peaked at $6.75M in Q2 2014. 75 funds tracked by Wall St. Rank hold RPRX as of Q3 2014.

  • Camber Capital Management reported no remaining Repros Therapeutics Inc. position as of Q3 2014 after selling out during the quarter.
  • Camber Capital Management sold 390,370 Repros Therapeutics Inc. shares in Q3 2014, an estimated $6.75M.
  • Camber Capital Management first reported a position in Repros Therapeutics Inc. in Q2 2014 and held it in 1 quarter.
  • Camber Capital Management's Repros Therapeutics Inc. position peaked at $6.75M in Q2 2014.
  • 75 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q3 2014.

Based on Camber Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.